Ran Mo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ran Mo has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Shiyang Shen
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China
18 shared publicationsXiao Xu
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China
14 shared publicationsYing Zhang
China Pharmaceutical University
11 shared publicationsTianyue Jiang
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China
10 shared publicationsTeng Li
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China
8 shared publicationsShiqi Lin
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China
7 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Nature Communications
Programmable hydrogel-nanocapsule protein delivery system targeting dense cartilage regeneration for osteoarthritis therapy
- 30 October 2026
- Published by Springer Nature in Nature Communications
Open AccessProgrammable hydrogel-nanocapsule protein delivery system targeting dense cartilage regeneration for osteoarthritis therapy
- 28 September 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (39) , 13335-13347
Bis(phosphoramidate diester)-Based Ionizable Lipids for Highly Efficient Lung-Selective mRNA Delivery via Intercellular Transport
Highly efficient lung-selective mRNA delivery is pivotal for advancing mRNA-based targeted therapy. Here, we report bis(phosphoramidate diester)-based ionizable cationic lipids (bpLs) for lung-specific mRNA delivery via a distinct intercellular transport mechanism. A bpL library is synthesized by modular headgroups (Ha), linkers (Lb), and tails (Tc). In vivo screening identifies the formulated bpLH15L2T8/DOPENP as the top lung-selective lipid nanoparticle (LNP) with superior pulmonary mRNA transfection. We elucidate that mononuclear phagocyte-guided cell-to-cell trafficking of bpLH15L2T8/DOPENP contributes to its high efficiency and selectivity of mRNA expression in lung tissue. p53 mRNA (mp53) delivered by bpLH15L2T8/DOPENP restores p53 function in p53-deficient pulmonary metastases and synergizes with immune checkpoint inhibitors to enhance antitumor immunity and inhibit lung metastasis of triple-negative breast cancer (TNBC). An all-trans retinoic acid (ATRA) prodrug-containing bpLNP is further developed for lung-specific codelivery of ATRA and mp53, which effectively suppresses lung metastasis of cancer stem cell-enriched TNBC.
- 28 September 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (39) , 13335-13347
Bis(phosphoramidate diester)-Based Ionizable Lipids for Highly Efficient Lung-Selective mRNA Delivery via Intercellular Transport
Highly efficient lung-selective mRNA delivery is pivotal for advancing mRNA-based targeted therapy. Here, we report bis(phosphoramidate diester)-based ionizable cationic lipids (bpLs) for lung-specific mRNA delivery via a distinct intercellular transport mechanism. A bpL library is synthesized by modular headgroups (Ha), linkers (Lb), and tails (Tc). In vivo screening identifies the formulated bpLH15L2T8/DOPENP as the top lung-selective lipid nanoparticle (LNP) with superior pulmonary mRNA transfection. We elucidate that mononuclear phagocyte-guided cell-to-cell trafficking of bpLH15L2T8/DOPENP contributes to its high efficiency and selectivity of mRNA expression in lung tissue. p53 mRNA (mp53) delivered by bpLH15L2T8/DOPENP restores p53 function in p53-deficient pulmonary metastases and synergizes with immune checkpoint inhibitors to enhance antitumor immunity and inhibit lung metastasis of triple-negative breast cancer (TNBC). An all-trans retinoic acid (ATRA) prodrug-containing bpLNP is further developed for lung-specific codelivery of ATRA and mp53, which effectively suppresses lung metastasis of cancer stem cell-enriched TNBC.
- 23 July 2026
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (8) , 1203-1214
Immunostimulatory lipogel implant enhances cancer immunotherapy
- 23 July 2026
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (8) , 1203-1214
Immunostimulatory lipogel implant enhances cancer immunotherapy
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 59, 678-696
Boosting ribosomal translation via ionizable lipid-hydrogel microplexes for localized mRNA therapy
MRNA therapy holds immense promise for regenerative medicine; however, localized endoplasmic reticulum stress (ERS) in damaged tissues can impair the critical process of ribosomal translation. Here, we developed an in situ injectable lipid nanoparticle (LNP)/microsphere complex, also referred to as a lipid-hydrogel microplex (iLMP), with ERS-alleviating functionality to increase ribosomal translation. A vitamin E-derived ionizable lipid was synthesized to replace conventional ionizable lipids in LNPs, whereas porous hydrogel microspheres stabilized the LNPs via physical adsorption. In vitro studies revealed that the iLMPs codelivered vitamin E and mRNA, mitigating ERS and reducing eIF2α phosphorylation, a key translational barrier. Additionally, iLMPs injected in situ rapidly reconstructed the extracellular matrix, promoting tissue repair. In a bone defect animal model, iLMPs significantly enhanced BMP-2 mRNA translation, promoting osteogenesis. In summary, we present a novel in situ injectable mRNA delivery platform that enhances ribosomal translation, offering a promising strategy for tissue regeneration.
- 1 May 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 59, 678-696
Open AccessBoosting ribosomal translation via ionizable lipid-hydrogel microplexes for localized mRNA therapy
MRNA therapy holds immense promise for regenerative medicine; however, localized endoplasmic reticulum stress (ERS) in damaged tissues can impair the critical process of ribosomal translation. Here, we developed an in situ injectable lipid nanoparticle (LNP)/microsphere complex, also referred to as a lipid-hydrogel microplex (iLMP), with ERS-alleviating functionality to increase ribosomal translation. A vitamin E-derived ionizable lipid was synthesized to replace conventional ionizable lipids in LNPs, whereas porous hydrogel microspheres stabilized the LNPs via physical adsorption. In vitro studies revealed that the iLMPs codelivered vitamin E and mRNA, mitigating ERS and reducing eIF2α phosphorylation, a key translational barrier. Additionally, iLMPs injected in situ rapidly reconstructed the extracellular matrix, promoting tissue repair. In a bone defect animal model, iLMPs significantly enhanced BMP-2 mRNA translation, promoting osteogenesis. In summary, we present a novel in situ injectable mRNA delivery platform that enhances ribosomal translation, offering a promising strategy for tissue regeneration.
- 6 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114909
Advances in hybrid hydrogels for diabetic wound healing
- 6 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114909
Advances in hybrid hydrogels for diabetic wound healing
- 16 May 2025
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (5) , 513-528
Advances in nanocarriers for targeted drug delivery and controlled drug release
- 16 May 2025
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (5) , 513-528
Advances in nanocarriers for targeted drug delivery and controlled drug release
- Top Cited Papers
- 6 May 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113825
Programmable hierarchical hydrogel dressing for sequential release of growth factor and DNase to accelerate diabetic wound healing
- 6 May 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113825
Top Cited PapersProgrammable hierarchical hydrogel dressing for sequential release of growth factor and DNase to accelerate diabetic wound healing
- 3 October 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (41) , 28081-28094
Stabilized Cell Membrane-Derived Vesicles by Lipid Anchoring for Enhanced Drug Delivery
A cell membrane-derived vesicle (MV) that has cell-mimicking features with characteristic functionalities holds vast appeal for biomimetic nanomedicine and drug delivery but suffers from a major limitation of innate fragility and poor stability. Herein, we report a lipid-anchoring strategy for stabilizing MV for enhanced drug delivery. An array of amphiphilic mono-acyl phosphatidylcholines (MPCs) with specific hydrophobic moieties are synthesized and readily engineered on MV based on their commendable aqueous solubility and efficient membrane insertability. Incorporation of MPCs containing rigid ring structures in the hydrophobic segment demonstrates the potency of stabilizing MV by the combined ordering and condensing effects. The optimized MPC-stabilized MV exhibits prolonged circulation in the bloodstream, elevated accumulation within a tumor, and enhanced therapeutic effects of chemotherapeutic and photothermal drugs. Moreover, doxorubicin-loaded MV, engineered with mono-all-trans retinoyl phosphatidylcholine as an MV stabilizer and a therapeutic prodrug, potently suppresses growth and metastasis of high-stemness tumors.
- 3 October 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (41) , 28081-28094
Stabilized Cell Membrane-Derived Vesicles by Lipid Anchoring for Enhanced Drug Delivery
A cell membrane-derived vesicle (MV) that has cell-mimicking features with characteristic functionalities holds vast appeal for biomimetic nanomedicine and drug delivery but suffers from a major limitation of innate fragility and poor stability. Herein, we report a lipid-anchoring strategy for stabilizing MV for enhanced drug delivery. An array of amphiphilic mono-acyl phosphatidylcholines (MPCs) with specific hydrophobic moieties are synthesized and readily engineered on MV based on their commendable aqueous solubility and efficient membrane insertability. Incorporation of MPCs containing rigid ring structures in the hydrophobic segment demonstrates the potency of stabilizing MV by the combined ordering and condensing effects. The optimized MPC-stabilized MV exhibits prolonged circulation in the bloodstream, elevated accumulation within a tumor, and enhanced therapeutic effects of chemotherapeutic and photothermal drugs. Moreover, doxorubicin-loaded MV, engineered with mono-all-trans retinoyl phosphatidylcholine as an MV stabilizer and a therapeutic prodrug, potently suppresses growth and metastasis of high-stemness tumors.
- 23 September 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 375, 589-600
Targeting the GTPase RAN by liposome delivery for tackling cancer stemness-emanated therapeutic resistance
- 23 September 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 375, 589-600
Targeting the GTPase RAN by liposome delivery for tackling cancer stemness-emanated therapeutic resistance
- Open Access
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation
The longevity of grafts remains a major challenge in allogeneic transplantation due to immune rejection. Systemic immunosuppression can impair graft function and can also cause severe adverse effects. Here, we report a local immuno-protective strategy to enhance post-transplant persistence of allografts using a mesenchymal stem cell membrane-derived vesicle (MMV)-crosslinked hydrogel (MMV-Gel). MMVs are engineered to upregulate expression of Fas ligand (FasL) and programmed death ligand 1 (PD-L1). The MMVs are retained within the hydrogel by crosslinking. The immuno-protective microenvironment of the hydrogel protects allografts by presenting FasL and PD-L1. The binding of these ligands to T effector cells, the dominant contributors to graft destruction and rejection, results in apoptosis of T effector cells and generation of regulatory T cells. We demonstrate that implantation with MMV-Gel prolongs the survival and function of grafts in mouse models of allogeneic pancreatic islet cells and skin transplantation.
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Open AccessImmuno-protective vesicle-crosslinked hydrogel for allogenic transplantation
The longevity of grafts remains a major challenge in allogeneic transplantation due to immune rejection. Systemic immunosuppression can impair graft function and can also cause severe adverse effects. Here, we report a local immuno-protective strategy to enhance post-transplant persistence of allografts using a mesenchymal stem cell membrane-derived vesicle (MMV)-crosslinked hydrogel (MMV-Gel). MMVs are engineered to upregulate expression of Fas ligand (FasL) and programmed death ligand 1 (PD-L1). The MMVs are retained within the hydrogel by crosslinking. The immuno-protective microenvironment of the hydrogel protects allografts by presenting FasL and PD-L1. The binding of these ligands to T effector cells, the dominant contributors to graft destruction and rejection, results in apoptosis of T effector cells and generation of regulatory T cells. We demonstrate that implantation with MMV-Gel prolongs the survival and function of grafts in mouse models of allogeneic pancreatic islet cells and skin transplantation.